|
Delaware
|
|
|
(State or Other Jurisdiction of Incorporation)
|
|
|
|
|
001-01011
|
|
05-0494040
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
One CVS Drive
|
|
Woonsocket, Rhode Island
|
02895
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Item 9.01 |
Financial Statements and Exhibits
|
Exhibit
No. |
|
Description
|
|
||||
CVS HEALTH CORPORATION
|
||||
Date: February 4, 2019
|
By: | /s/ Colleen M. McIntosh | ||
Colleen M. McIntosh | ||||
Senior Vice President, Corporate
Secretary and Assistant General Counsel |
||||
(Unaudited)
|
||||||||
(Millions)
|
September 30,
2018 |
December 31,
2017 |
||||||
Assets:
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
6,769
|
$
|
4,076
|
||||
Investments
|
2,796
|
2,280
|
||||||
Premiums receivable, net
|
2,484
|
2,240
|
||||||
Other receivables, net
|
3,220
|
2,831
|
||||||
Reinsurance recoverables
|
1,063
|
1,050
|
||||||
Income taxes receivable
|
—
|
365
|
||||||
Other current assets
|
3,039
|
2,681
|
||||||
Total current assets
|
19,371
|
15,523
|
||||||
Long-term investments
|
15,764
|
17,793
|
||||||
Reinsurance recoverables
|
3,177
|
3,323
|
||||||
Goodwill
|
10,576
|
10,571
|
||||||
Other acquired intangible assets, net
|
1,058
|
1,180
|
||||||
Property and equipment, net
|
568
|
586
|
||||||
Deferred income taxes
|
127
|
195
|
||||||
Other long-term assets
|
2,257
|
1,684
|
||||||
Separate Accounts assets
|
4,205
|
4,296
|
||||||
Total assets
|
$
|
57,103
|
$
|
55,151
|
||||
Liabilities and shareholders’ equity:
|
||||||||
Current liabilities:
|
||||||||
Health care costs payable
|
$
|
5,831
|
$
|
5,815
|
||||
Future policy benefits
|
565
|
604
|
||||||
Unpaid claims
|
826
|
850
|
||||||
Unearned premiums
|
749
|
654
|
||||||
Policyholders’ funds
|
3,019
|
2,918
|
||||||
Current portion of long-term debt
|
375
|
999
|
||||||
Income taxes payable
|
83
|
—
|
||||||
Accrued expenses and other current liabilities
|
5,222
|
4,997
|
||||||
Total current liabilities
|
16,670
|
16,837
|
||||||
Future policy benefits
|
5,568
|
5,763
|
||||||
Unpaid claims
|
1,918
|
1,922
|
||||||
Policyholders’ funds
|
636
|
739
|
||||||
Long-term debt, less current portion
|
7,782
|
8,160
|
||||||
Other long-term liabilities
|
1,761
|
1,597
|
||||||
Separate Accounts liabilities
|
4,205
|
4,296
|
||||||
Total liabilities
|
38,540
|
39,314
|
||||||
Commitments and contingencies (Note 14)
|
||||||||
Shareholders’ equity:
|
||||||||
Common stock ($.01 par value; 2.5 billion shares authorized and 327.4 million shares issued and outstanding in 2018; 2.5 billion shares authorized and 326.8 million shares issued and outstanding in 2017) and additional paid-in capital
|
4,779
|
4,706
|
||||||
Retained earnings
|
15,325
|
12,118
|
||||||
Accumulated other comprehensive loss
|
(1,813
|
)
|
(1,244
|
)
|
||||
Total Aetna shareholders’ equity
|
18,291
|
15,580
|
||||||
Non-controlling interests
|
272
|
257
|
||||||
Total equity
|
18,563
|
15,837
|
||||||
Total liabilities and equity
|
$
|
57,103
|
$
|
55,151
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions, except per common share data)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Revenue:
|
||||||||||||||||
Premiums
|
$
|
13,237
|
$
|
13,272
|
$
|
39,663
|
$
|
40,810
|
||||||||
Fees and other revenue
(1)
|
2,068
|
1,443
|
6,152
|
4,404
|
||||||||||||
Net investment income
|
202
|
233
|
605
|
730
|
||||||||||||
Net realized capital (losses) gains
|
(23
|
)
|
46
|
(40
|
)
|
(262
|
)
|
|||||||||
Total revenue
|
15,484
|
14,994
|
46,380
|
45,682
|
||||||||||||
Benefits and expenses:
|
||||||||||||||||
Benefit costs
(2)
|
10,852
|
10,960
|
32,096
|
33,537
|
||||||||||||
Cost of products sold
(1)
|
390
|
—
|
1,154
|
—
|
||||||||||||
Operating expenses
|
2,742
|
2,612
|
8,298
|
9,017
|
||||||||||||
Interest expense
|
85
|
90
|
262
|
349
|
||||||||||||
Amortization of other acquired intangible assets
|
48
|
58
|
142
|
176
|
||||||||||||
Loss on early extinguishment of long-term debt
|
—
|
—
|
—
|
246
|
||||||||||||
Reduction of reserve for anticipated future losses on discontinued products
|
—
|
—
|
(70
|
)
|
(109
|
)
|
||||||||||
Total benefits and expenses
|
14,117
|
13,720
|
41,882
|
43,216
|
||||||||||||
Income before income taxes
|
1,367
|
1,274
|
4,498
|
2,466
|
||||||||||||
Income taxes:
|
||||||||||||||||
Current
|
248
|
470
|
901
|
955
|
||||||||||||
Deferred
|
127
|
(44
|
)
|
169
|
(140
|
)
|
||||||||||
Total income tax expense
|
375
|
426
|
1,070
|
815
|
||||||||||||
Net income including non-controlling interests
|
992
|
848
|
3,428
|
1,651
|
||||||||||||
Less: Net (loss) income attributable to non-controlling interests
|
(8
|
)
|
10
|
7
|
(9
|
)
|
||||||||||
Net income attributable to Aetna
|
$
|
1,000
|
$
|
838
|
$
|
3,421
|
$
|
1,660
|
||||||||
Earnings per common share:
|
||||||||||||||||
Basic
|
$
|
3.05
|
$
|
2.54
|
$
|
10.44
|
$
|
4.95
|
||||||||
Diluted
|
$
|
3.03
|
$
|
2.52
|
$
|
10.37
|
$
|
4.92
|
(1) |
Fees and other revenue include administrative services contract member co-payments and plan sponsor reimbursements related to our home delivery and specialty pharmacy operations of $31 million and $100 million (net of pharmaceutical and processing costs of $350 million and $1.0 billion) for the three and nine months ended September 30, 2017, respectively. As a result of the adoption of new accounting guidance related to revenue recognition from contracts with customers for the three and nine months ended September 30, 2018, (a) specialty and home delivery pharmacy revenue reflects the price of the prescription on a gross basis and (b) specialty and home delivery pharmacy costs of products sold reflects the cost of the prescription and certain administrative expenses. Refer to Note 2 for further discussion.
|
(2) |
Health care costs have been reduced by Insured member co-payments related to our home delivery and specialty pharmacy operations of $26 million and $86 million for the three and nine months ended September 30, 2018, respectively, and $30 million and $96 million for the three and nine months ended September 30, 2017, respectively.
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Net income including non-controlling interests
|
$
|
992
|
$
|
848
|
$
|
3,428
|
$
|
1,651
|
||||||||
Other comprehensive income (loss), net of tax:
|
||||||||||||||||
Previously impaired debt securities
|
—
|
(1
|
)
|
(1
|
)
|
(2
|
)
|
|||||||||
All other securities
|
(11
|
)
|
8
|
(328
|
)
|
132
|
||||||||||
Derivatives and foreign currency
|
2
|
1
|
—
|
229
|
||||||||||||
Pension and other postretirement employee benefit plans
|
12
|
11
|
37
|
32
|
||||||||||||
Other comprehensive income (loss)
|
3
|
19
|
(292
|
)
|
391
|
|||||||||||
Comprehensive income including non-controlling interests
|
995
|
867
|
3,136
|
2,042
|
||||||||||||
Less: Comprehensive (loss) income attributable to non-controlling interests
|
(8
|
)
|
10
|
7
|
(9
|
)
|
||||||||||
Comprehensive income attributable to Aetna
|
$
|
1,003
|
$
|
857
|
$
|
3,129
|
$
|
2,051
|
Attributable to Aetna
|
||||||||||||||||||||||||||||
(Millions)
|
Number of Common Shares Outstanding
|
Common Stock and Additional Paid-in Capital
|
Retained Earnings
|
Accumulated Other Comprehensive Loss
|
Total Aetna Shareholders’ Equity
|
Non-Controlling Interests
|
Total Equity
|
|||||||||||||||||||||
Nine Months Ended September 30, 2018
|
||||||||||||||||||||||||||||
Balance at December 31, 2017
|
326.8
|
$
|
4,706
|
$
|
12,118
|
$
|
(1,244
|
)
|
$
|
15,580
|
$
|
257
|
$
|
15,837
|
||||||||||||||
Adoption of new accounting standards (Note 2)
|
—
|
—
|
277
|
(277
|
)
|
—
|
—
|
—
|
||||||||||||||||||||
Net income
|
—
|
—
|
1,209
|
—
|
1,209
|
10
|
1,219
|
|||||||||||||||||||||
Other comprehensive loss
|
—
|
—
|
—
|
(208
|
)
|
(208
|
)
|
—
|
(208
|
)
|
||||||||||||||||||
Common shares issued for benefit plans, including tax benefits, net of employee tax withholdings
|
0.3
|
(19
|
)
|
—
|
—
|
(19
|
)
|
—
|
(19
|
)
|
||||||||||||||||||
Dividends declared
|
—
|
—
|
(164
|
)
|
—
|
(164
|
)
|
—
|
(164
|
)
|
||||||||||||||||||
Balance at March 31, 2018
|
327.1
|
4,687
|
13,440
|
(1,729
|
)
|
16,398
|
267
|
16,665
|
||||||||||||||||||||
Net income
|
—
|
—
|
1,212
|
—
|
1,212
|
5
|
1,217
|
|||||||||||||||||||||
Other decreases in non-controlling
interest
|
—
|
—
|
—
|
—
|
—
|
(4
|
)
|
(4
|
)
|
|||||||||||||||||||
Other comprehensive loss
|
—
|
—
|
—
|
(87
|
)
|
(87
|
)
|
—
|
(87
|
)
|
||||||||||||||||||
Common shares issued for benefit plans, including tax benefits, net of employee tax withholdings
|
0.3
|
43
|
—
|
—
|
43
|
—
|
43
|
|||||||||||||||||||||
Dividends declared
|
—
|
—
|
(163
|
)
|
—
|
(163
|
)
|
—
|
(163
|
)
|
||||||||||||||||||
Balance at June 30, 2018
|
327.4
|
4,730
|
14,489
|
(1,816
|
)
|
17,403
|
268
|
17,671
|
||||||||||||||||||||
Net income (loss)
|
—
|
—
|
1,000
|
—
|
1,000
|
(8
|
)
|
992
|
||||||||||||||||||||
Other increases in non-controlling interest
|
—
|
—
|
—
|
—
|
—
|
12
|
12
|
|||||||||||||||||||||
Other comprehensive income (Note 11)
|
—
|
—
|
—
|
3
|
3
|
—
|
3
|
|||||||||||||||||||||
Common shares issued for benefit plans, including tax benefits, net of employee tax withholdings
|
—
|
49
|
—
|
—
|
49
|
—
|
49
|
|||||||||||||||||||||
Dividends declared
|
—
|
—
|
(164
|
)
|
—
|
(164
|
)
|
—
|
|
(164
|
)
|
|||||||||||||||||
Balance at September 30, 2018
|
327.4
|
$
|
4,779
|
$
|
15,325
|
$
|
(1,813
|
)
|
$
|
18,291
|
$
|
272
|
$
|
18,563
|
Attributable to Aetna
|
||||||||||||||||||||||||||||
(Millions)
|
Number of Common Shares Outstanding
|
Common Stock and Additional Paid-in Capital
|
Retained Earnings
|
Accumulated Other Comprehensive Loss
|
Total Aetna Shareholders’ Equity
|
Non-Controlling Interests
|
Total Equity
|
|||||||||||||||||||||
Nine Months Ended September 30, 2017
|
||||||||||||||||||||||||||||
Balance at December 31, 2016
|
351.7
|
$
|
4,716
|
$
|
14,717
|
$
|
(1,552
|
)
|
$
|
17,881
|
$
|
62
|
$
|
17,943
|
||||||||||||||
Net (loss) income
|
—
|
—
|
(381
|
)
|
—
|
(381
|
)
|
2
|
(379
|
)
|
||||||||||||||||||
Other increases in non-controlling interest
|
—
|
—
|
—
|
—
|
—
|
13
|
13
|
|||||||||||||||||||||
Other comprehensive income
|
—
|
—
|
—
|
276
|
276
|
—
|
276
|
|||||||||||||||||||||
Common shares issued for benefit plans, including tax benefits, net of employee tax withholdings
|
0.9
|
(49
|
)
|
—
|
—
|
(49
|
)
|
—
|
(49
|
)
|
||||||||||||||||||
Repurchases of common shares
|
(20.9
|
)
|
(661
|
)
|
(2,639
|
)
|
—
|
(3,300
|
)
|
—
|
(3,300
|
)
|
||||||||||||||||
Dividends declared
|
—
|
—
|
(166
|
)
|
—
|
(166
|
)
|
—
|
(166
|
)
|
||||||||||||||||||
Balance at March 31, 2017
|
331.7
|
4,006
|
11,531
|
(1,276
|
)
|
14,261
|
77
|
14,338
|
||||||||||||||||||||
Net income (loss)
|
—
|
—
|
1,203
|
—
|
1,203
|
(21
|
)
|
1,182
|
||||||||||||||||||||
Other increases in non-controlling interest
|
—
|
—
|
—
|
—
|
—
|
115
|
115
|
|||||||||||||||||||||
Other comprehensive income
|
—
|
—
|
—
|
96
|
96
|
—
|
96
|
|||||||||||||||||||||
Common shares issued for benefit plans, including tax benefits, net of employee tax withholdings
|
0.4
|
10
|
—
|
—
|
10
|
—
|
10
|
|||||||||||||||||||||
Dividends declared
|
—
|
—
|
(166
|
)
|
—
|
(166
|
)
|
—
|
(166
|
)
|
||||||||||||||||||
Balance at June 30, 2017
|
332.1
|
4,016
|
12,568
|
(1,180
|
)
|
15,404
|
171
|
15,575
|
||||||||||||||||||||
Net income
|
—
|
—
|
838
|
—
|
838
|
10
|
848
|
|||||||||||||||||||||
Other increases in non-controlling interest
|
—
|
—
|
—
|
—
|
—
|
54
|
54
|
|||||||||||||||||||||
Other comprehensive income (Note 11)
|
—
|
—
|
—
|
19
|
19
|
—
|
19
|
|||||||||||||||||||||
Common shares issued for benefit plans, including tax benefits, net of employee tax withholdings
|
0.1
|
30
|
—
|
—
|
30
|
—
|
30
|
|||||||||||||||||||||
Repurchases of common shares
|
(6.1
|
)
|
661
|
(1,206
|
)
|
—
|
(545
|
)
|
—
|
(545
|
)
|
|||||||||||||||||
Dividends declared
|
—
|
—
|
(163
|
)
|
—
|
(163
|
)
|
—
|
(163
|
)
|
||||||||||||||||||
Balance at September 30, 2017
|
326.1
|
$
|
4,707
|
$
|
12,037
|
$
|
(1,161
|
)
|
$
|
15,583
|
$
|
235
|
$
|
15,818
|
Nine Months Ended
September 30, |
||||||||
(Millions)
|
2018
|
2017
|
||||||
Cash flows from operating activities:
|
||||||||
Net income including non-controlling interests
|
$
|
3,428
|
$
|
1,651
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Net realized capital losses
|
40
|
262
|
||||||
Depreciation and amortization
|
400
|
499
|
||||||
Debt fair value amortization
|
(10
|
)
|
(14
|
)
|
||||
Equity in earnings of affiliates, net
|
(30
|
)
|
(80
|
)
|
||||
Stock-based compensation expense
|
125
|
135
|
||||||
Reduction of reserve for anticipated future losses on discontinued products
|
(70
|
)
|
(109
|
)
|
||||
Amortization of net investment premium
|
38
|
54
|
||||||
Loss on early extinguishment of long-term debt
|
—
|
246
|
||||||
Gain on sale of businesses
|
(355
|
)
|
—
|
|||||
Changes in assets and liabilities:
|
||||||||
Premiums due and other receivables
|
(486
|
)
|
(184
|
)
|
||||
Income taxes
|
625
|
(15
|
)
|
|||||
Other assets and other liabilities
|
136
|
(1,196
|
)
|
|||||
Health care and insurance liabilities
|
(156
|
)
|
931
|
|||||
Distributions from partnership investments
|
—
|
44
|
||||||
Net cash provided by operating activities
|
3,685
|
2,224
|
||||||
Cash flows from investing activities:
|
||||||||
Proceeds from sales and maturities of investments
|
7,164
|
8,854
|
||||||
Cost of investments
|
(6,235
|
)
|
(7,860
|
)
|
||||
Additions to property, equipment and software
|
(336
|
)
|
(301
|
)
|
||||
Cash used for acquisitions, net of cash acquired
|
(8
|
)
|
(24
|
)
|
||||
Net cash provided by investing activities
|
585
|
669
|
||||||
Cash flows from financing activities:
|
||||||||
Issuance of long-term debt
|
—
|
988
|
||||||
Repayment of long-term debt
|
(1,000
|
)
|
(11,734
|
)
|
||||
Common shares issued under benefit plans, net
|
(95
|
)
|
(132
|
)
|
||||
Common shares repurchased
|
—
|
(3,845
|
)
|
|||||
Dividends paid to shareholders
|
(491
|
)
|
(420
|
)
|
||||
Contributions, non-controlling interests
|
9
|
182
|
||||||
Net cash used for financing activities
|
(1,577
|
)
|
(14,961
|
)
|
||||
Net increase (decrease) in cash and cash equivalents
|
2,693
|
(12,068
|
)
|
|||||
Cash and cash equivalents, beginning of period
|
4,076
|
17,996
|
||||||
Cash and cash equivalents, end of period
|
$
|
6,769
|
$
|
5,928
|
||||
Supplemental cash flow information:
|
||||||||
Interest paid
|
$
|
212
|
$
|
301
|
||||
Income taxes paid
|
446
|
791
|
• |
Products for which we no longer solicit or accept new customers such as our large case pensions and long-term care products;
|
• |
Contracts we have divested through reinsurance or other contracts, such as our domestic group life insurance, group disability insurance and absence management businesses; and
|
• |
Corporate expenses not supporting our business operations, including transaction and integration-related costs, income taxes, interest expense on our outstanding debt and the financing components of our pension and other postretirement employee benefit plans (“OPEB”) expense.
|
September 30, 2018
|
December 31, 2017
|
|||||||||||||||||||||||
(Millions)
|
Current
|
Long-term
|
Total
|
Current
|
Long-term
|
Total
|
||||||||||||||||||
Debt securities available for sale
|
$
|
2,646
|
$
|
13,073
|
$
|
15,719
|
$
|
2,101
|
$
|
14,849
|
$
|
16,950
|
||||||||||||
Mortgage loans
|
150
|
1,228
|
1,378
|
166
|
1,330
|
1,496
|
||||||||||||||||||
Other investments
|
—
|
1,463
|
1,463
|
13
|
1,614
|
1,627
|
||||||||||||||||||
Total investments
|
$
|
2,796
|
$
|
15,764
|
$
|
18,560
|
$
|
2,280
|
$
|
17,793
|
$
|
20,073
|
(Millions)
|
Amortized Cost
|
Gross Unrealized Gains
|
Gross Unrealized Losses
|
Fair Value
|
||||||||||||
September 30, 2018
|
||||||||||||||||
Debt securities:
|
||||||||||||||||
U.S. government securities
|
$
|
1,686
|
$
|
19
|
$
|
(3
|
)
|
$
|
1,702
|
|||||||
States, municipalities and political subdivisions
|
2,484
|
54
|
(28
|
)
|
2,510
|
|||||||||||
U.S. corporate securities
|
6,653
|
176
|
(110
|
)
|
6,719
|
|||||||||||
Foreign securities
|
2,395
|
88
|
(46
|
)
|
2,437
|
|||||||||||
Residential mortgage-backed securities
|
611
|
1
|
(14
|
)
|
598
|
|||||||||||
Commercial mortgage-backed securities
|
610
|
—
|
(25
|
)
|
585
|
|||||||||||
Other asset-backed securities
|
1,143
|
2
|
(8
|
)
|
1,137
|
|||||||||||
Redeemable preferred securities
|
29
|
2
|
—
|
31
|
||||||||||||
Total debt securities
(1)(2)
|
$
|
15,611
|
$
|
342
|
$
|
(234
|
)
|
$
|
15,719
|
|||||||
December 31, 2017
|
||||||||||||||||
Debt securities:
|
||||||||||||||||
U.S. government securities
|
$
|
1,319
|
$
|
44
|
$
|
(1
|
)
|
$
|
1,362
|
|||||||
States, municipalities and political subdivisions
|
3,287
|
116
|
(12
|
)
|
3,391
|
|||||||||||
U.S. corporate securities
|
6,886
|
388
|
(22
|
)
|
7,252
|
|||||||||||
Foreign securities
|
2,498
|
187
|
(7
|
)
|
2,678
|
|||||||||||
Residential mortgage-backed securities
|
570
|
5
|
(4
|
)
|
571
|
|||||||||||
Commercial mortgage-backed securities
|
641
|
3
|
(9
|
)
|
635
|
|||||||||||
Other asset-backed securities
|
1,031
|
8
|
(4
|
)
|
1,035
|
|||||||||||
Redeemable preferred securities
|
22
|
4
|
—
|
26
|
||||||||||||
Total debt securities
(1)(2)
|
$
|
16,254
|
$
|
755
|
$
|
(59
|
)
|
$
|
16,950
|
(1) |
At both September 30, 2018 and December 31, 2017, we held securities for which we previously recognized an immaterial amount of non-credit related impairments in accumulated other comprehensive loss. These securities had an immaterial amount of net unrealized capital gains at both September 30, 2018 and December 31, 2017.
|
(2) |
Investment risks associated with our experience-rated and discontinued products generally do not impact our operating results (refer to Note 16 for additional information on our accounting for discontinued products). At September 30, 2018, debt securities with a fair value of approximately $2.3 billion, gross unrealized capital gains of $80 million and gross unrealized capital losses of $55 million and, at December 31, 2017, debt securities with a fair value of approximately $2.6 billion, gross unrealized capital gains of $199 million and gross unrealized capital losses of $8 million were included in total debt securities, but support our experience-rated and discontinued products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income.
|
(Millions)
|
Amortized Cost
|
Fair Value
|
||||||
Due to mature:
|
||||||||
Less than one year
|
$
|
817
|
$
|
824
|
||||
One year through five years
|
5,694
|
5,700
|
||||||
After five years through ten years
|
3,078
|
3,055
|
||||||
Greater than ten years
|
3,658
|
3,820
|
||||||
Residential mortgage-backed securities
|
611
|
598
|
||||||
Commercial mortgage-backed securities
|
610
|
585
|
||||||
Other asset-backed securities
|
1,143
|
1,137
|
||||||
Total
|
$
|
15,611
|
$
|
15,719
|
Less than 12 months
|
Greater than 12 months
|
Total
(1)
|
||||||||||||||||||||||||||||||||||
(Millions, except number of securities)
|
Number of
Securities
|
Fair Value
|
Unrealized
Losses
|
Number of
Securities
|
Fair Value
|
Unrealized
Losses
|
Number of
Securities
|
Fair Value
|
Unrealized
Losses
|
|||||||||||||||||||||||||||
September 30, 2018
|
||||||||||||||||||||||||||||||||||||
Debt securities:
|
||||||||||||||||||||||||||||||||||||
U.S. government securities
|
137
|
$
|
500
|
$
|
2
|
26
|
$
|
75
|
$
|
1
|
163
|
$
|
575
|
$
|
3
|
|||||||||||||||||||||
States, municipalities and political subdivisions
|
497
|
1,132
|
18
|
89
|
233
|
10
|
586
|
1,365
|
28
|
|||||||||||||||||||||||||||
U.S. corporate securities
|
2,391
|
3,589
|
73
|
450
|
662
|
37
|
2,841
|
4,251
|
110
|
|||||||||||||||||||||||||||
Foreign securities
|
777
|
1,187
|
35
|
126
|
205
|
11
|
903
|
1,392
|
46
|
|||||||||||||||||||||||||||
Residential mortgage-backed securities
|
119
|
396
|
7
|
125
|
156
|
7
|
244
|
552
|
14
|
|||||||||||||||||||||||||||
Commercial mortgage-backed securities
|
99
|
293
|
9
|
84
|
252
|
16
|
183
|
545
|
25
|
|||||||||||||||||||||||||||
Other asset-backed securities
|
442
|
669
|
5
|
65
|
136
|
3
|
507
|
805
|
8
|
|||||||||||||||||||||||||||
Redeemable preferred securities
|
4
|
5
|
—
|
—
|
—
|
—
|
4
|
5
|
—
|
|||||||||||||||||||||||||||
Total debt securities
(1)
|
4,466
|
$
|
7,771
|
$
|
149
|
965
|
$
|
1,719
|
$
|
85
|
5,431
|
$
|
9,490
|
$
|
234
|
|||||||||||||||||||||
December 31, 2017
|
||||||||||||||||||||||||||||||||||||
Debt securities:
|
||||||||||||||||||||||||||||||||||||
U.S. government securities
|
77
|
$
|
200
|
$
|
1
|
14
|
$
|
22
|
$
|
—
|
91
|
$
|
222
|
$
|
1
|
|||||||||||||||||||||
States, municipalities and political subdivisions
|
318
|
616
|
4
|
111
|
308
|
8
|
429
|
924
|
12
|
|||||||||||||||||||||||||||
U.S. corporate securities
|
989
|
1,469
|
6
|
284
|
494
|
16
|
1,273
|
1,963
|
22
|
|||||||||||||||||||||||||||
Foreign securities
|
262
|
419
|
3
|
91
|
194
|
4
|
353
|
613
|
7
|
|||||||||||||||||||||||||||
Residential mortgage-backed securities
|
111
|
179
|
1
|
98
|
134
|
3
|
209
|
313
|
4
|
|||||||||||||||||||||||||||
Commercial mortgage-backed securities
|
38
|
135
|
1
|
79
|
241
|
8
|
117
|
376
|
9
|
|||||||||||||||||||||||||||
Other asset-backed securities
|
150
|
304
|
2
|
79
|
151
|
2
|
229
|
455
|
4
|
|||||||||||||||||||||||||||
Total debt securities
(1)
|
1,945
|
$
|
3,322
|
$
|
18
|
756
|
$
|
1,544
|
$
|
41
|
2,701
|
$
|
4,866
|
$
|
59
|
(1) |
At September 30, 2018 and December 31, 2017, debt securities in an unrealized capital loss position of $55 million and $8 million, respectively, and with related fair value of $1.4 billion and $515 million, respectively, related to experience-rated and discontinued products.
|
Supporting discontinued and experience-rated products
|
Supporting remaining products
|
Total
|
||||||||||||||||||||||
(Millions)
|
Fair Value
|
Unrealized
Losses
|
Fair Value
|
Unrealized Losses
|
Fair Value
|
Unrealized
Losses
|
||||||||||||||||||
Due to mature:
|
||||||||||||||||||||||||
Less than one year
|
$
|
8
|
$
|
—
|
$
|
423
|
$
|
2
|
$
|
431
|
$
|
2
|
||||||||||||
One year through five years
|
238
|
5
|
3,118
|
47
|
3,356
|
52
|
||||||||||||||||||
After five years through ten years
|
498
|
18
|
1,523
|
43
|
2,021
|
61
|
||||||||||||||||||
Greater than ten years
|
456
|
24
|
1,324
|
48
|
1,780
|
72
|
||||||||||||||||||
Residential mortgage-backed securities
|
33
|
1
|
519
|
13
|
552
|
14
|
||||||||||||||||||
Commercial mortgage-backed securities
|
139
|
7
|
406
|
18
|
545
|
25
|
||||||||||||||||||
Other asset-backed securities
|
15
|
—
|
790
|
8
|
805
|
8
|
||||||||||||||||||
Total
|
$
|
1,387
|
$
|
55
|
$
|
8,103
|
$
|
179
|
$
|
9,490
|
$
|
234
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
New mortgage loans
|
$
|
42
|
$
|
27
|
$
|
90
|
$
|
209
|
||||||||
Mortgage loans fully repaid
|
53
|
90
|
175
|
190
|
• |
Category 1 -
Represents loans of superior quality.
|
• |
Categories 2 to 4
- Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes.
|
• |
Categories 5 and 6
- Represent loans where credit risk is not substantial, but these loans warrant management’s close attention.
|
• |
Category 7
- Represents loans where collections are potentially at risk; if necessary, an impairment is recorded.
|
(Millions)
|
September 30, 2018
|
December 31, 2017
|
||||||
1
|
$
|
41
|
$
|
40
|
||||
2 to 4
|
1,322
|
1,447
|
||||||
5 and 6
|
15
|
9
|
||||||
7
|
—
|
—
|
||||||
Total
|
$
|
1,378
|
$
|
1,496
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Debt securities
|
$
|
148
|
$
|
184
|
$
|
435
|
$
|
564
|
||||||||
Mortgage loans
|
18
|
22
|
57
|
65
|
||||||||||||
Other investments
|
47
|
43
|
143
|
138
|
||||||||||||
Gross investment income
|
213
|
249
|
635
|
767
|
||||||||||||
Investment expenses
|
(11
|
)
|
(16
|
)
|
(30
|
)
|
(37
|
)
|
||||||||
Net investment income
(1)
|
$
|
202
|
$
|
233
|
$
|
605
|
$
|
730
|
(1) |
Net investment income includes $44 million and $140 million for the three and nine months ended September 30, 2018, respectively, and $61 million and $186 million for the three and nine months ended September 30, 2017, respectively, related to investments supporting our experience-rated and discontinued products.
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Other-than-temporary impairment (“OTTI”) losses on debt securities recognized in earnings
|
$
|
(14
|
)
|
$
|
(3
|
)
|
$
|
(33
|
)
|
$
|
(5
|
)
|
||||
Other net realized capital (losses) gains
|
(9
|
)
|
49
|
(7
|
)
|
(257
|
)
|
|||||||||
Net realized capital (losses) gains
|
$
|
(23
|
)
|
$
|
46
|
$
|
(40
|
)
|
$
|
(262
|
)
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Proceeds on sales
|
$
|
1,215
|
$
|
1,181
|
$
|
4,367
|
$
|
3,827
|
||||||||
Gross realized capital gains
|
7
|
18
|
43
|
57
|
||||||||||||
Gross realized capital losses
|
15
|
6
|
54
|
31
|
• |
Hedge fund and private equity investments
- We invest in hedge fund and private equity investments in order to generate investment returns for our investment portfolio supporting our businesses.
|
• |
Real estate partnerships
- We invest in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to us are from tax credits and other tax benefits.
|
(Millions)
|
September 30, 2018
|
December 31, 2017
|
||||||
Hedge fund investments
|
$
|
282
|
$
|
351
|
||||
Private equity investments
|
511
|
453
|
||||||
Real estate partnerships
|
248
|
247
|
||||||
Total
|
$
|
1,041
|
$
|
1,051
|
(Millions)
|
September 30, 2018
|
December 31, 2017
|
||||||
Assets:
|
||||||||
Hedge fund investments
|
$
|
45,661
|
$
|
54,789
|
||||
Private equity investments
|
29,423
|
27,342
|
||||||
Real estate partnerships
|
6,296
|
6,451
|
||||||
Total
|
$
|
81,380
|
$
|
88,582
|
||||
Liabilities:
|
||||||||
Hedge fund investments
|
$
|
9,713
|
$
|
12,073
|
||||
Private equity investments
|
2,583
|
2,461
|
||||||
Real estate partnerships
|
4,635
|
4,691
|
||||||
Total
|
$
|
16,931
|
$
|
19,225
|
◦ |
Level 1
– Unadjusted quoted prices for identical assets or liabilities in active markets.
|
◦ |
Level 2
– Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
|
◦ |
Level 3
– Developed from unobservable data, reflecting our own assumptions.
|
(Millions)
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||
September 30, 2018
|
||||||||||||||||
Assets:
|
||||||||||||||||
Debt securities:
|
||||||||||||||||
U.S. government securities
|
$
|
1,622
|
$
|
80
|
$
|
—
|
$
|
1,702
|
||||||||
States, municipalities and political subdivisions
|
—
|
2,510
|
—
|
2,510
|
||||||||||||
U.S. corporate securities
|
—
|
6,625
|
94
|
6,719
|
||||||||||||
Foreign securities
|
—
|
2,434
|
3
|
2,437
|
||||||||||||
Residential mortgage-backed securities
|
—
|
598
|
—
|
598
|
||||||||||||
Commercial mortgage-backed securities
|
—
|
585
|
—
|
585
|
||||||||||||
Other asset-backed securities
|
—
|
1,137
|
—
|
1,137
|
||||||||||||
Redeemable preferred securities
|
—
|
24
|
7
|
31
|
||||||||||||
Total debt securities
|
1,622
|
13,993
|
104
|
15,719
|
||||||||||||
Equity securities
|
19
|
—
|
49
|
68
|
||||||||||||
Total
|
$
|
1,641
|
$
|
13,993
|
$
|
153
|
$
|
15,787
|
||||||||
December 31, 2017
|
||||||||||||||||
Assets:
|
||||||||||||||||
Debt securities:
|
||||||||||||||||
U.S. government securities
|
$
|
1,313
|
$
|
49
|
$
|
—
|
$
|
1,362
|
||||||||
States, municipalities and political subdivisions
|
—
|
3,390
|
1
|
3,391
|
||||||||||||
U.S. corporate securities
|
—
|
7,167
|
85
|
7,252
|
||||||||||||
Foreign securities
|
—
|
2,675
|
3
|
2,678
|
||||||||||||
Residential mortgage-backed securities
|
—
|
571
|
—
|
571
|
||||||||||||
Commercial mortgage-backed securities
|
—
|
635
|
—
|
635
|
||||||||||||
Other asset-backed securities
|
—
|
1,035
|
—
|
1,035
|
||||||||||||
Redeemable preferred securities
|
—
|
19
|
7
|
26
|
||||||||||||
Total debt securities
|
1,313
|
15,541
|
96
|
16,950
|
||||||||||||
Equity securities
|
43
|
—
|
27
|
70
|
||||||||||||
Total
|
$
|
1,356
|
$
|
15,541
|
$
|
123
|
$
|
17,020
|
Estimated Fair Value
|
||||||||||||||||||||
(Millions)
|
Carrying Value
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||||
September 30, 2018
|
||||||||||||||||||||
Assets:
|
||||||||||||||||||||
Mortgage loans
|
$
|
1,378
|
$
|
—
|
$
|
—
|
$
|
1,382
|
$
|
1,382
|
||||||||||
Bank loans
|
6
|
—
|
—
|
6
|
6
|
|||||||||||||||
Equity securities
(1)
|
49
|
N/A
|
N/A
|
N/A
|
N/A
|
|||||||||||||||
Liabilities:
|
||||||||||||||||||||
Investment contract liabilities:
|
||||||||||||||||||||
With a fixed maturity
|
5
|
—
|
—
|
5
|
5
|
|||||||||||||||
Without a fixed maturity
|
371
|
—
|
—
|
343
|
343
|
|||||||||||||||
Long-term debt
|
8,157
|
—
|
8,359
|
—
|
8,359
|
|||||||||||||||
(Millions)
|
||||||||||||||||||||
December 31, 2017
|
||||||||||||||||||||
Assets:
|
||||||||||||||||||||
Mortgage loans
|
$
|
1,496
|
$
|
—
|
$
|
—
|
$
|
1,524
|
$
|
1,524
|
||||||||||
Bank loans
|
7
|
—
|
—
|
7
|
7
|
|||||||||||||||
Equity securities
(1)
|
45
|
N/A
|
N/A
|
N/A
|
N/A
|
|||||||||||||||
Liabilities:
|
||||||||||||||||||||
Investment contract liabilities:
|
||||||||||||||||||||
With a fixed maturity
|
7
|
—
|
—
|
7
|
7
|
|||||||||||||||
Without a fixed maturity
|
363
|
—
|
—
|
354
|
354
|
|||||||||||||||
Long-term debt
|
9,159
|
—
|
9,815
|
—
|
9,815
|
(1) |
It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies.
|
September 30, 2018
|
December 31, 2017
|
|||||||||||||||||||||||||||||||
(Millions)
|
Level 1
|
Level 2
|
Level 3
|
Total
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||||||||||||||
Debt securities
|
$
|
900
|
$
|
2,596
|
$
|
—
|
$
|
3,496
|
$
|
1,085
|
$
|
2,611
|
$
|
2
|
$
|
3,698
|
||||||||||||||||
Equity securities
|
—
|
6
|
—
|
6
|
—
|
6
|
—
|
6
|
||||||||||||||||||||||||
Common/collective trusts
|
—
|
422
|
—
|
422
|
—
|
448
|
—
|
448
|
||||||||||||||||||||||||
Total
(1)
|
$
|
900
|
$
|
3,024
|
$
|
—
|
$
|
3,924
|
$
|
1,085
|
$
|
3,065
|
$
|
2
|
$
|
4,152
|
(1) |
Excludes $281 million and $144 million of cash and cash equivalents and other receivables at September 30, 2018 and December 31, 2017, respectively.
|
Nine Months Ended
September 30, |
||||||||
(Millions)
|
2018
|
2017
|
||||||
Health care costs payable, beginning of the period
|
$
|
5,815
|
$
|
6,558
|
||||
Less: Reinsurance recoverables
|
6
|
5
|
||||||
Health care costs payable, beginning of the period, net
|
5,809
|
6,553
|
||||||
Add: Components of incurred health care costs
|
||||||||
Current year
|
32,231
|
32,611
|
||||||
Prior years
|
(416
|
)
|
(783
|
)
|
||||
Total incurred health care costs
(1)
|
31,815
|
31,828
|
||||||
Less: Claims paid
|
||||||||
Current year
|
26,856
|
26,959
|
||||||
Prior years
|
4,946
|
5,364
|
||||||
Total claims paid
|
31,802
|
32,323
|
||||||
Health care costs payable, end of period, net
|
5,822
|
6,058
|
||||||
Add: Premium deficiency reserve
|
6
|
77
|
||||||
Add: Reinsurance recoverables
|
3
|
4
|
||||||
Health care costs payable, end of period
|
$
|
5,831
|
$
|
6,139
|
(1) |
The nine months ended September 30, 2018 total incurred health care costs in the table above exclude $6 million related to a premium deficiency reserve for the 2018 coverage year related to our Medicaid products. The nine months ended September 30, 2017 total incurred health care costs in the table above exclude $77 million primarily related to a premium deficiency reserve for the 2017 coverage year related to our individual Commercial products. Total incurred health care costs for the nine months ended September 30, 2018 and 2017 in the table above also exclude $36 million and $37 million, respectively, of benefit costs recorded in our Health Care segment that are included in our unpaid claims liability.
|
(Millions)
|
September 30, 2018
|
December 31, 2017
|
||||||
Senior notes, 1.7% due June 2018
(1)
|
$
|
—
|
$
|
999
|
||||
Senior notes, 2.2% due March 2019
(1)
|
375
|
374
|
||||||
Senior notes, 5.45% due June 2021
|
637
|
647
|
||||||
Senior notes, 4.125% due June 2021
|
497
|
496
|
||||||
Senior notes, 2.75% due November 2022
|
990
|
988
|
||||||
Senior notes, 2.8% due June 2023
|
1,292
|
1,292
|
||||||
Senior notes, 3.5% due November 2024
|
744
|
743
|
||||||
Senior notes, 6.625% due June 2036
|
766
|
766
|
||||||
Senior notes, 6.75% due December 2037
|
528
|
527
|
||||||
Senior notes, 4.5% due May 2042
|
479
|
479
|
||||||
Senior notes, 4.125% due November 2042
|
490
|
489
|
||||||
Senior notes, 4.75% due March 2044
|
371
|
371
|
||||||
Senior notes, 3.875% due August 2047
|
988
|
988
|
||||||
Total long-term debt
|
8,157
|
9,159
|
||||||
Less current portion of long-term debt
|
375
|
999
|
||||||
Total long-term debt, less current portion
|
$
|
7,782
|
$
|
8,160
|
(1) |
At September 30, 2018, our 2.2% senior notes due March 2019 were classified as current in our Consolidated Balance Sheet. At December 31, 2017, our 1.7% senior notes due June 2018 were classified as current in our Consolidated Balance Sheet.
|
Pension Plans
|
OPEB Plans
|
|||||||||||||||||||||||||||||||
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
2018
|
2017
|
2018
|
2017
|
||||||||||||||||||||||||
Amortization of prior service credit
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
(1
|
)
|
$
|
(1
|
)
|
$
|
(3
|
)
|
$
|
(3
|
)
|
||||||||||||
Interest cost
|
50
|
51
|
150
|
153
|
2
|
2
|
6
|
6
|
||||||||||||||||||||||||
Expected return on plan assets
|
(102
|
)
|
(95
|
)
|
(306
|
)
|
(285
|
)
|
—
|
—
|
(2
|
)
|
(3
|
)
|
||||||||||||||||||
Recognized net actuarial losses
|
16
|
16
|
48
|
48
|
1
|
1
|
3
|
3
|
||||||||||||||||||||||||
Net periodic (income) benefit cost
|
$
|
(36
|
)
|
$
|
(28
|
)
|
$
|
(108
|
)
|
$
|
(84
|
)
|
$
|
2
|
$
|
2
|
$
|
4
|
$
|
3
|
Date Declared
|
Dividend Amount Per Share
|
Shareholders of Record Date
|
Date Paid/ To be Paid
|
Total Dividends (Millions)
|
||||||||
Nine months ended September 30, 2018
|
||||||||||||
February 23, 2018
|
$
|
.50
|
April 12, 2018
|
April 27, 2018
|
$
|
164
|
||||||
May 18, 2018
|
$
|
.50
|
July 25, 2018
|
August 1, 2018
|
$
|
164
|
||||||
September 28, 2018
|
$
|
.50
|
October 24, 2018
|
November 1, 2018
|
$
|
164
|
2017
|
||||
Expected term (in years)
|
7.21
|
|||
Volatility
|
26.52
|
%
|
||
Risk-free interest rate
|
2.22
|
%
|
||
Dividend yield
|
1.71
|
%
|
||
Initial price
|
$
|
125.27
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Previously impaired debt securities:
(1)
|
||||||||||||||||
Beginning of period balance
|
$
|
5
|
$
|
15
|
$
|
5
|
$
|
16
|
||||||||
Adoption of new accounting standard (Note 2)
|
—
|
—
|
1
|
—
|
||||||||||||
Net unrealized losses (
$(14), $(5), $(34) and $(8) pretax)
|
(11
|
)
|
(3
|
)
|
(27
|
)
|
(5
|
)
|
||||||||
Less: Net reclassification of losses to earnings
($(14), $(3), $(33) and $(5) pretax)
(2)
|
(11
|
)
|
(2
|
)
|
(26
|
)
|
(3
|
)
|
||||||||
Other comprehensive loss
|
—
|
(1
|
)
|
(1
|
)
|
(2
|
)
|
|||||||||
End of period balance
|
5
|
14
|
5
|
14
|
||||||||||||
All other securities:
|
||||||||||||||||
Beginning of period balance
|
74
|
421
|
326
|
297
|
||||||||||||
Adoption of new accounting standards (Note 2)
($0, $0, $7, and $0 pretax)
|
—
|
—
|
65
|
—
|
||||||||||||
Net unrealized (losses) gains (
$(32), $48, $(465) and $298 pretax)
|
(25
|
)
|
31
|
(367
|
)
|
194
|
||||||||||
Less: Net reclassification of (losses) gains to earnings (
$(18), $35, $(49) and $95 pretax)
(2)
|
(14
|
)
|
23
|
(39
|
)
|
62
|
||||||||||
Other comprehensive (loss) income
|
(11
|
)
|
8
|
(328
|
)
|
132
|
||||||||||
End of period balance
|
63
|
429
|
63
|
429
|
||||||||||||
Derivatives and foreign currency:
|
||||||||||||||||
Beginning of period balance
|
(7
|
)
|
(7
|
)
|
(4
|
)
|
(235
|
)
|
||||||||
Adoption of new accounting standard (Note 2)
|
—
|
—
|
(1
|
)
|
—
|
|||||||||||
Net unrealized gains
($0 $0, $0 and $8 pretax)
|
—
|
—
|
—
|
5
|
||||||||||||
Less: Net reclassification of losses to earnings
($(3), $(2), $0 and $(345) pretax)
(3)
|
(2
|
)
|
(1
|
)
|
—
|
(224
|
)
|
|||||||||
Other comprehensive income
|
2
|
1
|
—
|
229
|
||||||||||||
End of period balance
|
(5
|
)
|
(6
|
)
|
(5
|
)
|
(6
|
)
|
||||||||
Pension and OPEB plans:
|
||||||||||||||||
Beginning of period balance
|
(1,888
|
)
|
(1,609
|
)
|
(1,571
|
)
|
(1,630
|
)
|
||||||||
Adoption of new accounting standard (Note 2)
|
—
|
—
|
(342
|
)
|
—
|
|||||||||||
Less: Net amortization of net actuarial losses
($(16), $(17), $(51) and $(51) pretax)
(4)
|
(13
|
)
|
(12
|
)
|
(40
|
)
|
(34
|
)
|
||||||||
Less: Net amortization of prior service credit (
$1, $2, $3 and $3 pretax)
(4)
|
1
|
1
|
3
|
2
|
||||||||||||
Other comprehensive income
|
12
|
11
|
37
|
32
|
||||||||||||
End of period balance
|
(1,876
|
)
|
(1,598
|
)
|
(1,876
|
)
|
(1,598
|
)
|
||||||||
Total beginning of period accumulated other comprehensive loss
|
(1,816
|
)
|
(1,180
|
)
|
(1,244
|
)
|
(1,552
|
)
|
||||||||
Adoption of new accounting standards (Note 2)
|
—
|
—
|
(277
|
)
|
—
|
|||||||||||
Total other comprehensive income (loss)
|
3
|
19
|
(292
|
)
|
391
|
|||||||||||
Total end of period accumulated other comprehensive loss
|
$
|
(1,813
|
)
|
$
|
(1,161
|
)
|
$
|
(1,813
|
)
|
$
|
(1,161
|
)
|
(1) |
Represents specifically identified unrealized gains and losses on the non-credit related component of impaired debt securities that we do not intend to sell and subsequent changes in the fair value of any previously impaired security.
|
(2) |
Reclassifications out of accumulated other comprehensive income for specifically identified previously impaired debt securities and all other securities are reflected in net realized capital gains (losses) within our Consolidated Statements of Income.
|
(3) |
Reclassifications out of accumulated other comprehensive income for specifically identified foreign currency gains (losses) and derivatives are reflected in net realized capital gains (losses) within our Consolidated Statements of Income, except for the specifically identified effective portion of derivatives related to cash flow hedges which are reflected in interest expense. During the nine months ended September 30, 2017, we redeemed the entire $10.2 billion aggregate principal amount of the Special Mandatory Redemption Notes and the entire $750 million aggregate principal amount of the 2020 Notes and reclassified out of accumulated other comprehensive income the remaining $336 million pre-tax unrealized hedge losses as a realized capital loss within our Consolidated Statements of Income. Refer to Note 8 for additional information.
|
(4) |
Reclassifications out of accumulated other comprehensive income for specifically identified pension and OPEB plan expenses are reflected in operating expenses within our Consolidated Statements of Income. Refer to Note 9 for additional information.
|
12. |
Earnings Per Common Share
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions, except per common share data)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Net income attributable to Aetna
|
$
|
1,000
|
$
|
838
|
$
|
3,421
|
$
|
1,660
|
||||||||
Weighted average shares used to compute basic EPS
|
327.9
|
329.7
|
327.8
|
335.3
|
||||||||||||
Dilutive effect of outstanding stock-based compensation awards
|
2.3
|
2.3
|
2.1
|
2.2
|
||||||||||||
Weighted average shares used to compute diluted EPS
|
330.2
|
332.0
|
329.9
|
337.5
|
||||||||||||
Basic EPS
|
$
|
3.05
|
$
|
2.54
|
$
|
10.44
|
$
|
4.95
|
||||||||
Diluted EPS
|
$
|
3.03
|
$
|
2.52
|
$
|
10.37
|
$
|
4.92
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
SARs
(1)
|
—
|
—
|
—
|
—
|
||||||||||||
Other stock-based compensation awards
(2)
|
.2
|
.6
|
.5
|
.8
|
(1) |
SARs are excluded from the calculation of diluted EPS if the exercise price is greater than the average market price of Aetna common shares during the period (i.e., the awards are anti-dilutive).
|
(2) |
PSUs and certain market stock units with performance conditions are excluded from the calculation of diluted EPS if all necessary performance conditions have not been satisfied at the end of the reporting period.
|
(Millions)
|
Health Care
|
Corporate/Other
|
Total Company
|
|||||||||
Three Months Ended September 30, 2018
|
||||||||||||
Revenue from external customers
|
$
|
15,161
|
$
|
144
|
$
|
15,305
|
||||||
Pre-tax adjusted earnings (loss)
(2)
|
1,390
|
(45
|
)
|
1,345
|
||||||||
Three Months Ended September 30, 2017
|
||||||||||||
Revenue from external customers
|
$
|
14,146
|
$
|
569
|
$
|
14,715
|
||||||
Pre-tax adjusted earnings (loss)
(2)
|
1,301
|
(29
|
)
|
1,272
|
||||||||
Nine Months Ended September 30, 2018
|
||||||||||||
Revenue from external customers
|
$
|
45,393
|
$
|
422
|
$
|
45,815
|
||||||
Pre-tax adjusted earnings (loss)
(2)
|
4,478
|
(138
|
)
|
4,340
|
||||||||
Nine Months Ended September 30, 2017
|
||||||||||||
Revenue from external customers
|
$
|
43,534
|
$
|
1,680
|
$
|
45,214
|
||||||
Pre-tax adjusted earnings (loss)
(2)
|
4,556
|
(76
|
)
|
4,480
|
(1) |
Total assets by segment are not disclosed as this information is not reviewed by the chief executive officer.
|
(2) |
Pre-tax adjusted earnings (loss) excludes net realized capital gains or losses, amortization of other acquired intangible assets and the other items described in the reconciliation below.
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
(Millions)
|
2018
|
2017
|
2018
|
2017
|
||||||||||||
Income before income taxes (GAAP measure)
|
$
|
1,367
|
$
|
1,274
|
$
|
4,498
|
$
|
2,466
|
||||||||
Less: (Loss) income before income taxes attributable to non-controlling interests (GAAP measure)
|
(10
|
)
|
14
|
10
|
(6
|
)
|
||||||||||
Income before income taxes attributable to Aetna (GAAP measure)
|
1,377
|
1,260
|
4,488
|
2,472
|
||||||||||||
Gain related to sale of certain domestic group insurance businesses
|
(121
|
)
|
—
|
(355
|
)
|
—
|
||||||||||
Transaction and integration-related costs
|
18
|
—
|
95
|
1,202
|
||||||||||||
Reduction of reserve for anticipated future losses on discontinued products
|
—
|
—
|
(70
|
)
|
(109
|
)
|
||||||||||
Loss on early extinguishment of long-term debt
|
—
|
—
|
—
|
246
|
||||||||||||
Penn Treaty-related guaranty fund assessments
|
—
|
—
|
—
|
231
|
||||||||||||
Amortization of other acquired intangible assets
|
48
|
58
|
142
|
176
|
||||||||||||
Net realized capital losses (gains)
|
23
|
(46
|
)
|
40
|
262
|
|||||||||||
Pre-tax adjusted earnings
(1)
|
$
|
1,345
|
$
|
1,272
|
$
|
4,340
|
$
|
4,480
|
(1) |
In addition to net realized capital gains and losses and amortization of other acquired intangible assets, the following other items are excluded from adjusted earnings and pre-tax adjusted earnings because we believe they neither relate to the ordinary course of our business nor reflect our underlying business performance:
|
• |
During 2017, we sold our domestic group life insurance, group disability insurance and absence management businesses. The transaction was accomplished through an indemnity reinsurance arrangement. As used in this Quarterly Report on Form 10-Q with respect to the Group Insurance sale, the terms “gain”, “deferred gain” and “amortization of deferred gain” include both the deferred gain related to the retroactive provisions of the reinsurance contract and the prepaid reinsurance premium paid by HLAIC to Aetna (representing unearned ceding commission to Aetna) allocated to the prospective provisions of the reinsurance contract. A significant portion of the gain on sale has been deferred and will be amortized into earnings: (a) over the remaining contract period (estimated to be approximately 3 years at the closing date) in proportion to the amount of insurance protection provided for the prospective reinsurance portion of the gain; and (b) as we recover amounts due from HLAIC over a period estimated to be approximately 30 years at the closing date for the retrospective reinsurance portion of the gain. The gain recognized during the three and nine months ended September 30, 2018 does not directly relate to the underwriting or servicing of products for customers and is not directly related to the core performance of our business operations.
|
• |
We recorded transaction and integration-related costs during the three and nine months ended September 30, 2018 related to our proposed acquisition by CVS Health. We also recorded transaction and integration-related costs during the nine months ended September 30, 2017 primarily related to the Humana Transaction. Transaction costs include costs associated with the transactions contemplated by the CVS Merger Agreement, real estate costs associated with the cancellation of our previously announced headquarters relocation which will no longer occur due to CVS Health’s proposed acquisition of Aetna, the termination of the Humana Merger Agreement, the termination of our agreement to sell certain assets to Molina and advisory, legal and other professional fees which are reflected in our GAAP Consolidated Statements of Income in operating expenses. Transaction costs also include the negative cost of carry associated with the debt financing that we obtained in June 2016 for the Humana Transaction. Prior to the mandatory redemption of the Special Mandatory Redemption Notes, the negative cost of carry associated with these senior notes was excluded from adjusted earnings and pre-tax adjusted earnings. The negative cost of carry associated with the $2.8 billion aggregate principal amount of our senior notes issued in June 2016 that are not subject to mandatory redemption (the “Other 2016 Senior Notes”) was excluded from adjusted earnings and pre-tax adjusted earnings through the date of the termination of the Humana Merger Agreement. The components of the negative cost of carry are reflected in our GAAP Consolidated Statements of Income in interest expense and net investment income. Subsequent to the termination of the Humana Merger Agreement, the interest expense and net investment income associated with the Other 2016 Senior Notes were no longer excluded from adjusted earnings and pre-tax adjusted earnings.
|
• |
In 1993, we discontinued the sale of fully guaranteed large case pensions products and established a reserve for anticipated future losses on these products, which we review quarterly. During both the nine months ended September 30, 2018 and 2017, we reduced the reserve for anticipated future losses on discontinued products. We believe excluding any changes in the reserve for anticipated future losses on discontinued products from adjusted earnings provides more useful information as to our continuing products and is consistent with the treatment of the operating results of these discontinued products, which are credited or charged to the reserve and do not affect net income attributable to Aetna.
|
• |
During the nine months ended September 30, 2017, we incurred losses on the early extinguishment of long-term debt due to (a) the mandatory redemption of the $10.2 billion aggregate principal amount of the Special Mandatory Redemption Notes following the termination of the Humana Merger Agreement and (b) the early redemption of the entire $750 million aggregate principal amount of the 2020 Notes.
|
• |
During the nine months ended September 30, 2017, we recorded an expense for estimated future guaranty fund assessments related to Penn Treaty, which was placed in rehabilitation in 2009 and placed in liquidation in March 2017. This expense does not directly relate to the underwriting or servicing of products for customers and is not directly related to the core performance of our business operations.
|
16. |
Discontinued Products
|
(Millions)
|
2018
|
2017
|
||||||
Reserve, beginning of period
|
$
|
954
|
$
|
962
|
||||
Operating (loss) income
|
(9
|
)
|
34
|
|||||
Net realized capital gains
|
6
|
55
|
||||||
Reserve reduction
|
(70
|
)
|
(109
|
)
|
||||
Reserve, end of period
|
$
|
881
|
$
|
942
|
(Millions)
|
2018
|
2017
|
||||||
Assets:
|
||||||||
Debt and equity securities available for sale
|
$
|
1,415
|
$
|
1,623
|
||||
Mortgage loans
|
508
|
567
|
||||||
Other investments
|
589
|
564
|
||||||
Total investments
|
2,512
|
2,754
|
||||||
Other assets
|
67
|
71
|
||||||
Receivable from continuing products
(2)
|
439
|
474
|
||||||
Total assets
|
$
|
3,018
|
$
|
3,299
|
||||
Liabilities:
|
||||||||
Future policy benefits
|
$
|
2,052
|
$
|
2,165
|
||||
Reserve for anticipated future losses on discontinued products
|
881
|
954
|
||||||
Current and deferred income taxes
|
35
|
22
|
||||||
Other liabilities
(3)
|
50
|
158
|
||||||
Total liabilities
|
$
|
3,018
|
$
|
3,299
|
(1) |
Assets supporting the discontinued products are distinguished from assets supporting continuing products.
|
(2) |
At the time of discontinuance, a receivable from large case pensions’ continuing products was established on the discontinued products balance sheet. This receivable represented the net present value of anticipated cash shortfalls in the discontinued products, which will be funded from continuing products. Interest on the receivable is accrued at the discount rate that was used to calculate the reserve. The offsetting payable, on which interest is similarly accrued, is reflected in continuing products. Interest on the payable generally offsets investment income on the assets available to fund the shortfall. These amounts are eliminated in consolidation.
|
(3) |
Net unrealized capital gains on the available-for-sale debt securities are included in other liabilities and are not reflected in consolidated shareholders’ equity.
|
· |
separate audited historical consolidated financial statements of CVS Health as of and for the year ended December 31, 2017, and the related notes included in CVS Health’s Annual Report on Form 10-K for the year ended December 31, 2017;
|
· |
separate unaudited historical condensed consolidated financial statements of CVS Health as of and for the nine month period ended September 30, 2018, and the related notes included in CVS Health’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018;
|
· |
separate audited historical consolidated financial statements of Aetna as of and for the year ended December 31, 2017, and the related notes included in Aetna’s Annual Report on Form 10-K for the year ended December 31, 2017; and
|
· |
separate unaudited historical condensed consolidated financial statements of Aetna as of and for the nine month period ended September 30, 2018, and the related notes included in Aetna’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018.
|
Pro Forma
|
||||||||||||||||
Historical
|
Adjustments
|
Pro Forma
|
||||||||||||||
CVS Health
|
Aetna
|
(Note 6)
|
Combined
|
|||||||||||||
(in millions, except per common share data)
|
||||||||||||||||
Revenues:
|
||||||||||||||||
Pharmacy, consumer products and other:
|
||||||||||||||||
Net revenues
|
$
|
181,207
|
$
|
—
|
$
|
(9,165
|
)
(l)
|
$
|
172,042
|
|||||||
Insurance:
|
||||||||||||||||
Premiums
(k)
|
3,558
|
53,894
|
—
|
57,452
|
||||||||||||
Fees and other revenue
|
—
|
5,930
|
—
|
5,930
|
||||||||||||
Net investment income
|
21
|
711
|
(156
|
)
(m)
|
576
|
|||||||||||
Total net revenues
|
184,786
|
60,535
|
(9,321
|
)
|
236,000
|
|||||||||||
Operating costs and expenses:
|
||||||||||||||||
Pharmacy, consumer products and other:
|
||||||||||||||||
Cost of revenues
|
153,448
|
—
|
(8,148
|
)
(l)
|
145,300
|
|||||||||||
Insurance:
|
||||||||||||||||
Benefit costs
(k)
|
2,810
|
44,519
|
(927
|
)
(l)
|
46,402
|
|||||||||||
156,258
|
44,519
|
(9,075
|
)
|
191,702
|
||||||||||||
Selling, general and administrative expenses
|
18,809
|
12,336
|
819
|
(n)
|
31,964
|
|||||||||||
Goodwill impairments
|
181
|
—
|
181
|
|||||||||||||
Total operating costs and expenses
|
175,248
|
56,855
|
(8,256
|
)
|
223,847
|
|||||||||||
Operating income
|
9,538
|
3,680
|
(1,065
|
)
|
12,153
|
|||||||||||
Interest expense
|
1,062
|
442
|
1,927
|
(o)
|
3,431
|
|||||||||||
Loss on early extinguishment of debt
|
—
|
246
|
—
|
246
|
||||||||||||
Other expense (income)
|
208
|
—
|
(171
|
)
(p)
|
37
|
|||||||||||
Income from continuing operations before income tax provision
|
8,268
|
2,992
|
(2,821
|
)
|
8,439
|
|||||||||||
Income tax provision
|
1,637
|
1,087
|
(1,100
|
)
(q)
|
1,624
|
|||||||||||
Income from continuing operations
|
6,631
|
1,905
|
(1,721
|
)
|
6,815
|
|||||||||||
Income from continuing operations attributable to noncontrolling interests
|
(1
|
)
|
(1
|
)
|
—
|
(2
|
)
|
|||||||||
Income from continuing operations attributable to CVS Health
|
$
|
6,630
|
$
|
1,904
|
$
|
(1,721
|
)
|
$
|
6,813
|
|||||||
Earnings per share from continuing operations attributable to CVS Health:
|
||||||||||||||||
Basic
|
$
|
6.48
|
$
|
5.71
|
$
|
5.25
|
(s)
|
|||||||||
Diluted
|
$
|
6.45
|
$
|
5.68
|
$
|
5.21
|
(s)
|
|||||||||
Weighted average shares:
|
||||||||||||||||
Basic
|
1,020
|
333
|
(59
|
)
|
1,294
|
(r)
|
||||||||||
Diluted
|
1,024
|
335
|
(56
|
)
|
1,303
|
(r)
|
Pro Forma
|
||||||||||||||||
Historical
|
Adjustments
|
Pro Forma
|
||||||||||||||
CVS Health
|
Aetna
|
(Note 6)
|
Combined
|
|||||||||||||
(in millions, except per common share data)
|
||||||||||||||||
Revenues:
|
||||||||||||||||
Pharmacy, consumer products and other:
|
||||||||||||||||
Net revenues
|
$
|
136,986
|
$
|
—
|
$
|
(4,829
|
)
(l)
|
$
|
132,157
|
|||||||
Insurance:
|
||||||||||||||||
Premiums
(k)
|
2,684
|
39,663
|
—
|
42,347
|
||||||||||||
Fees and other revenue
|
—
|
6,152
|
—
|
6,152
|
||||||||||||
Net investment income
|
485
|
565
|
(578
|
)
(m)
|
472
|
|||||||||||
Total net revenues
|
140,155
|
46,380
|
(5,407
|
)
|
181,128
|
|||||||||||
Operating costs and expenses:
|
||||||||||||||||
Pharmacy, consumer products and other:
|
||||||||||||||||
Cost of revenues
|
115,883
|
1,154
|
(3,942
|
)
(l)
|
113,095
|
|||||||||||
Insurance:
|
||||||||||||||||
Benefit costs
(k)
|
2,399
|
32,026
|
(798
|
)
(l)
|
33,627
|
|||||||||||
118,282
|
33,180
|
(4,740
|
)
|
146,722
|
||||||||||||
Selling, general and administrative expenses
|
14,755
|
8,440
|
657
|
(n)
|
23,852
|
|||||||||||
Goodwill impairment
|
3,921
|
—
|
3,921
|
|||||||||||||
Total operating costs and expenses
|
136,958
|
41,620
|
(4,083
|
)
|
174,495
|
|||||||||||
Operating income
|
3,197
|
4,760
|
(1,324
|
)
|
6,633
|
|||||||||||
Interest expense
|
1,886
|
262
|
286
|
(o)
|
2,434
|
|||||||||||
Other expense (income)
|
7
|
—
|
(152
|
)
(p)
|
(145
|
)
|
||||||||||
Income from continuing operations before income tax provision
|
1,304
|
4,498
|
(1,458
|
)
|
4,344
|
|||||||||||
Income tax provision
|
1,478
|
1,070
|
(379
|
)
(q)
|
2,169
|
|||||||||||
Income (loss) from continuing operations
|
(174
|
)
|
3,428
|
(1,079
|
)
|
2,175
|
||||||||||
Income from continuing operations attributable to noncontrolling interests
|
—
|
(7
|
)
|
—
|
(7
|
)
|
||||||||||
Income from continuing operations attributable to CVS Health
|
$
|
(174
|
)
|
$
|
3,421
|
$
|
(1,079
|
)
|
$
|
2,168
|
||||||
Earnings per share from continuing operations attributable to CVS Health:
|
||||||||||||||||
Basic
|
$
|
(0.17
|
)
|
$
|
10.44
|
$
|
1.67
|
(s)
|
||||||||
Diluted
|
$
|
(0.17
|
)
|
$
|
10.37
|
$
|
1.67
|
(s)
|
||||||||
Weighted average shares:
|
||||||||||||||||
Basic
|
1,018
|
328
|
(54
|
)
|
1,292
|
(r)
|
||||||||||
Diluted
|
1,018
|
330
|
(49
|
)
|
1,299
|
(r)
|
|
||||||||||||||||
Pro Forma | ||||||||||||||||
Historical
|
Adjustments | Pro Forma | ||||||||||||||
CVS Health
|
Aetna
|
(Note 7)
|
Combined
|
|||||||||||||
(in millions)
|
||||||||||||||||
Assets:
|
||||||||||||||||
Cash and cash equivalents
|
$
|
41,587
|
$
|
6,769
|
$
|
(42,987
|
)
(t)
|
$
|
5,369
|
|||||||
Investments
|
105
|
2,796
|
—
|
2,901
|
||||||||||||
Accounts receivable, net
|
14,837
|
5,704
|
(1,682
|
)
(u)
|
18,859
|
|||||||||||
Inventories
|
14,818
|
6
|
—
|
14,824
|
||||||||||||
Other current assets
|
634
|
4,096
|
—
|
4,730
|
||||||||||||
Total current assets
|
71,981
|
19,371
|
(44,669
|
)
|
46,683
|
|||||||||||
Long-term investments
|
—
|
15,764
|
—
|
15,764
|
||||||||||||
Property and equipment, net
|
10,419
|
568
|
185
|
(v)
|
11,172
|
|||||||||||
Goodwill
|
34,216
|
10,576
|
35,972
|
(w)
|
80,764
|
|||||||||||
Intangible assets, net
|
13,166
|
1,058
|
22,558
|
(x)
|
36,782
|
|||||||||||
Separate Account assets
|
—
|
4,205
|
—
|
4,205
|
||||||||||||
Other assets
|
1,724
|
5,561
|
(1,409
|
)
(y)
|
5,876
|
|||||||||||
Total assets
|
$
|
131,506
|
$
|
57,103
|
$
|
12,637
|
$
|
201,246
|
||||||||
Liabilities and shareholders’ equity:
|
||||||||||||||||
Pharmacy claims and discounts payable
|
$
|
12,348
|
$
|
410
|
$
|
(805
|
)
(u)
|
$
|
11,953
|
|||||||
Health care costs payable and other insurance liabilities
|
—
|
7,222
|
(606
|
)
(u)
|
6,616
|
|||||||||||
Accrued expenses and other current liabilities
|
14,973
|
8,663
|
(451
|
)
(z)
|
23,185
|
|||||||||||
Short-term debt and current portion of long-term debt
|
2,139
|
375
|
—
|
2,514
|
||||||||||||
Total current liabilities
|
29,460
|
16,670
|
(1,862
|
)
|
44,268
|
|||||||||||
Long-term debt
|
60,747
|
7,782
|
4,923
|
(aa)
|
73,452
|
|||||||||||
Deferred income taxes
|
3,052
|
—
|
5,540
|
(bb)
|
8,592
|
|||||||||||
Separate Account liabilities
|
—
|
4,205
|
—
|
4,205
|
||||||||||||
Other insurance liabilities
|
—
|
7,486
|
259
|
(cc)
|
7,745
|
|||||||||||
Other long-term liabilities
|
1,625
|
2,397
|
(300
|
)
(dd)
|
3,722
|
|||||||||||
Total liabilities
|
94,884
|
38,540
|
8,560
|
141,984
|
||||||||||||
Shareholders’ equity:
|
||||||||||||||||
Common stock and capital surplus
(1)
|
32,377
|
4,779
|
(4,412
|
)
(ee)
|
32,744
|
|||||||||||
Treasury stock and shares held in trust
|
(37,731
|
)
|
—
|
22,117
|
(ff)
|
(15,614
|
)
|
|||||||||
Retained earnings
|
41,843
|
15,325
|
(15,498
|
)
(gg)
|
41,670
|
|||||||||||
Accumulated other comprehensive income (loss)
|
129
|
(1,813
|
)
|
1,813
|
(hh)
|
129
|
||||||||||
Total CVS Health shareholders’ equity
|
36,618
|
18,291
|
4,020
|
58,929
|
||||||||||||
Noncontrolling interests
|
4
|
272
|
57
|
(ii)
|
333
|
|||||||||||
Total shareholders’ equity
|
36,622
|
18,563
|
4,077
|
59,262
|
||||||||||||
Total liabilities and shareholders’ equity
|
$
|
131,506
|
$
|
57,103
|
$
|
12,637
|
$
|
201,246
|
(1) |
On an historical basis, share information of CVS Health is as follows: 3.2 billion shares of common stock authorized; 1.7 billion shares of common stock issued and 1.0 billion shares outstanding. On a pro forma combined basis, share information is as follows: 3.2 billion shares of common stock authorized; 2.0 billion shares of common stock issued and 1.293 billion shares of common stock outstanding.
|
(a) |
As further discussed in
Note 1. Description of Transaction
, certain outstanding equity awards granted to Aetna employees were not settled upon completion of the Merger, and instead were converted into replacement equity awards issued by CVS Health. CVS Health estimated the fair value of these replacement equity awards and attributed that fair value to pre-Merger and post-Merger services. $367 million of the fair value of these awards was attributed to pre-Merger services and is included in the other consideration transferred, and $232 million will be accounted for as compensation expense in CVS Health’s post-Merger financial statements. The final total consideration transferred also will reflect the effective settlement of pre-existing relationships between CVS Health and Aetna as of November 28, 2018.
|
As of
|
||||
September 30,
|
||||
2018
|
||||
(in millions)
|
||||
Assets Acquired and Liabilities Assumed:
|
||||
Historical net book value of net assets acquired
|
$
|
18,563
|
||
Less historical:
|
||||
Goodwill
|
(10,576
|
)
|
||
Intangible assets
|
(1,058
|
)
|
||
Debt issuance costs and net debt discounts/premiums
|
(47
|
)
|
||
Capitalized software
|
(785
|
)
|
||
Deferred acquisition costs
|
(612
|
)
|
||
Deferred gain related to Aetna’s Group Insurance sale
|
653
|
|||
Deferred tax assets on outstanding equity awards
|
(25
|
)
|
||
Deferred tax assets on net debt discounts/premiums
|
(8
|
)
|
||
Deferred tax assets on deferred gain liability related to Aetna’s Group Insurance sale
|
(137
|
)
|
||
Deferred tax liabilities on deferred acquisition costs
|
129
|
|||
Deferred tax liabilities on historical capitalized software
|
174
|
|||
Deferred tax liabilities on historical intangible assets and tax deductible goodwill
|
444
|
|||
Adjusted book value of net assets acquired
|
6,715
|
|||
Adjustments to:
|
||||
Goodwill
(b)
|
46,548
|
|||
Identifiable intangible assets
(c)
|
23,616
|
|||
Deferred tax liabilities
(d)
|
(6,117
|
)
|
||
Fair value adjustment to Aetna debt assumed
(e)
|
107
|
|||
Fair value adjustment to long duration insurance reserves
(f)
|
(259
|
)
|
||
Fair value adjustment to property and equipment
(g)
|
185
|
|||
Fair value of noncontrolling interests
(h)
|
(329
|
)
|
||
To record cash associated with the sale of Aetna’s standalone PDP plans
(i)
|
107
|
|||
Other
(j)
|
—
|
|||
Total adjustments
|
63,858
|
|||
Consideration transferred
|
$
|
70,573
|
(b) |
Goodwill is calculated as the difference between the acquisition date fair value of the total consideration transferred and the aggregate values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized.
|
(c) |
As of the completion of the Merger, identifiable intangible assets are required to be measured at fair value, and these acquired assets could include assets that are not intended to be used or sold or that are intended to be used in a manner other than their highest and best use. For purposes of these unaudited pro forma condensed combined financial statements and consistent with the ASC 820 requirements for fair value measurements, it is assumed that all acquired assets will be used, and that all acquired assets will be used in a manner that represents the highest and best use of those acquired assets. The estimated fair value of Aetna’s identifiable intangible assets excludes a held for sale customer relationship intangible asset related to Aetna’s standalone Medicare Part D prescription drug plans of $107 million that were divested on November 30, 2018 to WellCare Health Plans Inc. (“WellCare”). See
Note 8. Disposition
for further information.
|
Estimated
|
Estimated
|
|||||||
Fair Value
|
Useful Life
|
|||||||
|
(in millions)
|
(Years)
|
||||||
Customer relationships
|
$
|
13,600
|
14
|
|||||
Technology
|
1,060
|
3
|
||||||
Provider networks
|
4,200
|
20
|
||||||
Value of Business Acquired
|
591
|
20
|
||||||
Definite-lived trade names/trademarks
|
65
|
5
|
||||||
19,516
|
||||||||
Indefinite-lived trade name/trademark
|
4,100
|
N/A
|
||||||
Total
|
$
|
23,616
|
(d) |
As of the completion of the Merger, CVS Health established net deferred tax liabilities and made other tax adjustments as part of the accounting for the Merger, primarily related to estimated fair value adjustments for identifiable intangible assets, long duration insurance reserves, property and equipment and debt (see Note 5(c) and Notes 5(e) through 5(g)). The pro forma adjustment to record the effect of deferred taxes was computed as follows:
|
(e) |
As of the completion of the Merger, Aetna’s debt is required to be measured at fair value. As a result, CVS Health decreased the fair value of Aetna debt assumed by $107 million, which will be amortized over the life of the Aetna debt as an increase in interest expense. This adjustment reflects the aggregate difference between the par value and the fair value of Aetna’s long-term debt.
|
(f) |
As of the completion of the Merger, Aetna’s long duration insurance contract liabilities are required to be measured at fair value in accordance with ASC 944,
Financial Services - Insurance
.
|
(g) |
As of the completion of the Merger, Aetna’s property and equipment is required to be measured at fair value, unless those assets are classified as held-for-sale on the acquisition date. The acquired assets can include assets that are not intended to be used or sold, or that are intended to be used in a manner other than their highest and best use. The fair value of Aetna’s property and equipment reflects the value that a market participant would spend to replace the assets, which takes into account changes in technology, usage and relative obsolescence and depreciation of the assets.
|
(h) |
As of the completion of the Merger, the net book value of Aetna’s noncontrolling interests is required to be measured at fair value.
|
(i) |
To record the cash received related to the sale of Aetna’s standalone Medicare Part D prescription drug plans. See
Note 8. Disposition
for further information.
|
(j) |
As of the completion of the Merger, various other assets and liabilities are required to be measured at fair value, including, but not limited to: accounts receivable, investments and certain contingencies. At this time, CVS Health does not have sufficient information to make a reasonable preliminary estimate of the fair value of these assets and liabilities. Accordingly, for the purposes of these unaudited pro forma condensed combined financial statements, CVS Health has assumed that the historical Aetna book values represent the best estimate of fair value.
|
(k) |
For the year ended December 31, 2017 and the nine months ended September 30, 2018, CVS Health’s insurance premiums from its SilverScript Insurance Company prescription drug plan of $3.6 billion and $2.7 billion, respectively, have been reclassified and presented separately from net revenues from pharmacy, consumer products and other. The related benefit costs for the year ended December 31, 2017 and the nine months ended September 30, 2018 of $2.8 billion and $2.4 billion, respectively, have been reclassified and presented separately from cost of revenues from pharmacy, consumer products and other. These reclassifications made in these pro forma condensed combined financial statements were made to conform with Aetna’s insurance-related presentation.
|
(l) |
To eliminate pharmacy and clinical services revenue CVS Health earned from Aetna of $9.2 billion and $4.8 billion, respectively, for the year ended December 31, 2017 and for the nine months ended September 30, 2018. The related costs eliminated and their financial statement line items are as follows:
|
Year Ended
|
Nine Months Ended
|
|||||||
December 31, 2017
|
September 30, 2018
|
|||||||
(in millions)
|
||||||||
Elimination of cost of revenues
|
$
|
8,148
|
$
|
3,942
|
||||
Elimination of benefit costs
|
927
|
798
|
||||||
Elimination of administrative fees from selling, general and administrative expenses
|
90
|
89
|
||||||
Total elimination
|
$
|
9,165
|
$
|
4,829
|
(m) |
For the purposes of these unaudited pro forma condensed combined financial statements, this adjustment reflects CVS Health’s estimated forgone interest income associated with the following items:
|
Year Ended
|
Nine Months Ended
|
|||||||
December 31, 2017
|
September 30, 2018
|
|||||||
(in millions)
|
||||||||
CVS Health’s estimated foregone interest income associated with adjusting the amortized cost of Aetna’s debt securities investment portfolio to fair value as of the completion of the Merger.
|
$
|
(111
|
)
|
$
|
(73
|
)
|
||
CVS Health’s estimated foregone interest income associated with the cash used to partially fund a portion of the Merger Consideration. The estimated foregone interest income for the combined entity is based on a weighted average annual interest rate of 1.45% and 2.22% for the year ended December 31, 2017 and the nine months ended September 30, 2018, respectively.
|
(45
|
)
|
(51
|
)
|
||||
CVS Health’s estimated foregone interest income associated with the interest earned during the nine months ended September 30, 2018 on the net proceeds of CVS Health’s $40 billion debt issuance in March 2018 to partially fund the Merger.
|
—
|
(454
|
)
|
|||||
Estimated adjustment to net investment income
|
$
|
(156
|
)
|
$
|
(578
|
)
|
(n) |
During the first quarter of 2017, CVS Health early adopted ASU 2017-07,
Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
. ASU 2017-07 requires entities to disaggregate the current service cost component from the other components of net benefit cost and present it with other current compensation costs for related employees in the income statement and present the other components of net benefit cost elsewhere in the income statement and outside of operating income.
|
Year Ended
|
Nine Months Ended
|
|||||||
December 31, 2017
|
September 30, 2018
|
|||||||
(in millions)
|
||||||||
Net periodic benefit expense (income) for pension plans
|
$
|
(112
|
)
|
$
|
(108
|
)
|
||
Net periodic benefit expense for other postretirement employee benefit plans
|
5
|
4
|
||||||
Reclassification of net periodic benefit expense (income) from selling, general and administrative expenses to other expense (income)
|
$
|
(107
|
)
|
$
|
(104
|
)
|
Year Ended
|
Nine Months Ended
|
|||||||
December 31, 2017
|
September 30, 2018
|
|||||||
(in millions)
|
||||||||
Reclassification of net periodic benefit income to other expense (income), as discussed above
|
$
|
107
|
$
|
104
|
||||
Eliminate Aetna’s historical administrative fees paid to CVS Health (see Note 6(m))
|
(90
|
)
|
(89
|
)
|
||||
Eliminate CVS Health and Aetna transaction costs incurred
|
(72
|
)
|
(134
|
)
|
||||
Eliminate Aetna’s historical intangible asset amortization expense
|
(272
|
)
|
(142
|
)
|
||||
Eliminate Aetna’s historical deferred acquisition cost amortization expense
|
(111
|
)
|
(94
|
)
|
||||
Eliminate Aetna’s historical capitalized software amortization expense
|
(316
|
)
|
(167
|
)
|
||||
Estimated depreciation expense related to property and equipment fair value adjustment
|
24
|
18
|
||||||
Estimated transaction-related intangible asset amortization (*)
|
1,549
|
1,161
|
||||||
Estimated adjustment to selling, general and administrative expenses
|
$
|
819
|
$
|
657
|
(*)
|
Assumes an estimated $19.5 billion of finite-lived intangibles and a weighted average amortization period of approximately 17 years (See
Note 5. Estimate of Assets Acquired and Liabilities Assumed
).
|
(o) |
CVS estimates interest expense to increase due to the following:
|
Year Ended
|
Nine Months Ended
|
|||||||
December 31, 2017
|
September 30, 2018
|
|||||||
(in millions)
|
||||||||
Additional interest expense associated with the issuance of $40.0 billion of long-term fixed-rate and/or floating rate debt that CVS Health issued to partially fund the Merger with various maturity tranches ranging from 2 to 30 years and an assumed weighted average annual interest rate of 4.23% (**)
|
$
|
1,692
|
$
|
282
|
||||
Additional interest expense associated with the issuance of $5.0 billion of fixed-rate and/or floating rate term loans to partially fund the Merger Consideration with an assumed maturity of 3 to 5 years and an assumed weighted average annual interest rate of 4.07% (***)
|
||||||||
204
|
153
|
|||||||
Eliminate CVS Health bridge financing costs
|
(56
|
)
|
(173
|
)
|
||||
Eliminate historical amortization of net debt discounts/premiums and debt issuance costs
|
2
|
(1
|
)
|
|||||
Amortization of debt issuance costs and debt discounts associated with the long-term debt and term loans issued to partially fund the Merger
|
77
|
19
|
||||||
Amortization of the estimated fair value adjustment to Aetna’s debt assumed by CVS Health over the remaining life of Aetna’s outstanding debt
|
8
|
6
|
||||||
Estimated adjustment to interest expense
|
$
|
1,927
|
$
|
286
|
(**)
|
If interest rates were to increase or decrease by 0.125% from the floating rates assumed in estimating this pro forma adjustment to interest expense, pro forma interest expense would increase or decrease by approximately $2 million in the year ended December 31, 2017 and approximately $2 million in the nine months ended September 30, 2018.
|
(***)
|
If interest rates were to increase or decrease by 0.125% from the rates assumed in estimating this pro forma adjustment to interest expense, pro forma interest expense would increase or decrease by approximately $6 million in the year ended December 31, 2017 and $5 million in the nine months ended September 30, 2018.
|
(p) |
To adjust other expense (income) for the following:
|
Year Ended
|
Nine Months Ended
|
|||||||
December 31, 2017
|
September 30, 2018
|
|||||||
(in millions)
|
||||||||
Reclassification of net periodic benefit income from selling, general and administrative expenses to other expense (income) as discussed in Note 6(n)
|
$
|
(107
|
)
|
$
|
(104
|
)
|
||
Adjustment to net periodic benefit expense (income) to eliminate the amortization of prior service credit and deferred actuarial losses
|
(64
|
)
|
(48
|
)
|
||||
Total
|
$
|
(171
|
)
|
$
|
(152
|
)
|
(q) |
The pro forma income tax adjustments for the statement of income are estimated at the applicable statutory income tax rates, generally 39% for the year ended December 31, 2017 and 26% for the nine months ended September 30, 2018.
|
(r) |
The pro forma combined basic and diluted earnings per share for the periods presented are based on the combined weighted average basic and diluted common shares of CVS Health and Aetna. The historical weighted average basic and diluted shares of Aetna were assumed to be replaced by the shares of common stock issued by CVS Health to effect the Merger.
|
(s) |
The following is a reconciliation of pro forma combined basic and diluted earnings per share for the respective periods:
|
(t) |
To r
eflect
the use of available cash to partially fund the Merger. The components of such available cash were:
|
(in millions)
|
||||
To record issuance of CVS Health term loans to effect the Merger
|
$
|
5,000
|
||
To record cash received from the Divestiture
|
107
|
|||
Debt issuance costs to be paid after September 30, 2018
|
(5
|
)
|
||
To record the cash portion of the Merger Consideration
|
(48,089
|
)
|
||
Total
|
$
|
(42,987
|
)
|
(u) |
To eliminate trade receivables and payables between CVS Health and Aetna.
|
(v) |
To adjust property and equipment to their estimated fair value.
|
(w) |
To adjust goodwill to an estimate of acquisition date goodwill, as follows:
|
(in millions)
|
||||
Eliminate Aetna’s historical goodwill
|
$
|
(10,576
|
)
|
|
Estimated transaction goodwill
|
46,548
|
|||
Total
|
$
|
35,972
|
(x) |
To adjust intangible assets to their estimated fair value, as follows:
|
(in millions)
|
||||
Eliminate Aetna’s historical intangible assets
|
$
|
(1,058
|
)
|
|
Estimated fair value of intangible assets acquired
|
23,616
|
|||
Total
|
$
|
22,558
|
(y) |
To adjust other assets to their estimated fair value, as follows:
|
(in millions)
|
||||
Eliminate Aetna’s historical capitalized software
|
$
|
(785
|
)
|
|
Eliminate Aetna’s historical deferred acquisition costs
|
(612
|
)
|
||
Reclassify term loan facility fees paid in December 2017 as a reduction of long-term debt
|
(12
|
)
|
||
Total
|
$
|
(1,409
|
)
|
(z) |
To adjust accrued expenses and other current liabilities:
|
(aa) |
To record the issuance of CVS Health term loans to effect the Merger and related estimated debt issuance costs, eliminate the Aetna historical unamortized debt issuance costs and net debt discounts/premiums that have no future economic benefit, and adjust Aetna’s debt to an estimate of fair value, as follows:
|
(in millions)
|
||||
Establish incremental CVS Health term loans to effect the Merger
|
5,000
|
|||
Estimated debt issuance costs
|
(17
|
)
|
||
Elimination of unamortized debt issuance costs and net debt discounts/premiums
|
47
|
|||
Estimated fair value adjustment to Aetna debt assumed
|
(107
|
)
|
||
Total
|
$
|
4,923
|
(bb) |
Adjustment of deferred tax liabilities (assets) as follows:
|
(in millions)
|
||||
Eliminate Aetna’s historical deferred tax liability on intangible assets and tax deductible goodwill
|
$
|
(444
|
)
|
|
Eliminate Aetna’s historical deferred tax liability on capitalized software
|
(174
|
)
|
||
Eliminate Aetna’s historical deferred tax assets on net debt discounts/premiums
|
8
|
|||
Eliminate Aetna’s historical deferred tax asset on outstanding equity awards
|
25
|
|||
Eliminate Aetna’s historical deferred tax liability on deferred acquisition costs
|
(129
|
)
|
||
Eliminate Aetna’s historical deferred tax asset on the deferred gain related to the Group Insurance sale
|
137
|
|||
Estimated transaction-related deferred tax liability on identifiable intangible assets
|
6,108
|
|||
Estimated transaction-related deferred tax asset on fair value adjustment to long duration insurance reserves | (67 | ) | ||
Estimated transaction-related deferred tax liability on fair value adjustment to property and equipment | 48 | |||
Estimated transaction-related deferred tax
liability
for fair value decrease in assumed debt
|
28
|
|||
Total
|
$
|
5,540
|
(cc) |
To adjust Aetna’s long duration insurance contract liabilities to their estimated fair value.
|
(dd) |
To eliminate the long term portion of Aetna’s deferred gain related to the Group Insurance sale.
|
(ee) |
To eliminate Aetna’s historical common shares and additional paid-in capital and to record other consideration transferred related to the pre-Merger portion of the fair value of replacement equity awards issued by CVS Health as further described in
Note 4
.
Consideration Transferred
.
|
(in millions)
|
||||
Elimination of Aetna’s historical common shares and additional paid-in capital
|
$
|
(4,779
|
)
|
|
To record other consideration transferred
|
367
|
|||
Total
|
$
|
(4,412
|
)
|
(ff) |
Issuance of shares of CVS Health common stock from treasury stock to record the share consideration portion of the Merger Consideration.
|
(gg) |
To eliminate Aetna’s historical retained earnings and to record the estimated after-tax portion of the acquisition related transaction costs projected to be incurred after September 30, 2018:
|
(in millions)
|
||||
Elimination of Aetna’s historical retained earnings
|
$
|
(15,325
|
)
|
|
Acquisition-related transaction costs projected to be incurred after September 30, 2018
|
(173
|
)
|
||
Total
|
$
|
(15,498
|
)
|
(hh) |
To eliminate Aetna’s historical accumulated other comprehensive income.
|
(ii) |
To adjust Aetna’s noncontrolling interests to their estimated fair value.
|
|